Anti-osteosarcoma effect of antiserum against cross antigen TPD52 between osteosarcoma and Trichinella spiralis
Related Experiment Video
Updated: Oct 19, 2025
Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
Published on: November 8, 2016
Tao-Tao Yue1, Nan Zhang1, Jian-Hua Li1
1Key Laboratory of Zoonosis Research By Ministry of Education, Institute of Zoonosis, College of Veterinary Medicine, Jilin University, Changchun, 130062, China.
Background:
Trichinella spiralis (T. spiralis) is a parasite occurring worldwide that has been proven to have antitumour ability. However, studies on the antitumour effects of cross antigens between the tumour and T. spiralis or antibodies against cross antigens between tumours and T. spiralis are rare.
Methods:
To study the role of cross antigens between osteosarcoma and T. spiralis, we first screened the cDNA expression library of T. spiralis muscle larvae to obtain the cross antigen gene tumour protein D52 (TPD52), and prepared fusion protein TPD52 and its antiserum. The anti-osteosarcoma effect of the anti-TPD52 antiserum was studied using cell proliferation and cytotoxicity assays as well as in vivo animal models; preliminary data on the mechanism were obtained using western blot and immunohistochemistry analyses.
Results:
Our results indicated that TPD52 was mainly localized in the cytoplasm of MG-63 cells. Anti-TPD52 antiserum inhibited the proliferation of MG-63 cells and the growth of osteosarcoma in a dose-dependent manner. The tumour inhibition rate in the 100 μg treatment group was 61.95%. Enzyme-linked immunosorbent assay showed that injection of anti-TPD52 antiserum increased the serum levels of IFN-γ, TNF-α, and IL-12 in nude mice. Haematoxylin and eosin staining showed that anti-TPD52 antiserum did not cause significant pathological damage. Apoptosis of osteosarcoma cells was induced by anti-TPD52 antiserum in vivo and in vitro.
Conclusions:
Anti-TPD52 antiserum exerts an anti-osteosarcoma effect by inducing apoptosis without causing histopathological damage.
Insights
Antibodies targeting the Trichinella spiralis-derived TPD52 antigen show significant anti-osteosarcoma effects. This approach effectively inhibits tumor growth and induces cancer cell apoptosis without causing adverse pathological damage.
Area of Science:
- Immunology
- Parasitology
- Oncology
Background:
- Trichinella spiralis (T. spiralis) possesses known antitumour properties.
- Research on cross-reactive antigens between T. spiralis and tumors, or antibodies against them, is limited.
- Osteosarcoma remains a significant challenge in oncology.
Purpose of the Study:
- To investigate the potential of cross-reactive antigens between T. spiralis and osteosarcoma.
- To evaluate the anti-osteosarcoma efficacy of antibodies targeting the identified cross-antigen, TPD52.
Main Methods:
- Screened T. spiralis cDNA expression library to identify the cross-antigen tumor protein D52 (TPD52).
- Prepared TPD52 fusion protein and its corresponding antiserum.
- Assessed anti-osteosarcoma effects using cell proliferation, cytotoxicity assays, in vivo models, western blot, and immunohistochemistry.
Main Results:
- TPD52 was identified as a cross-antigen, localized in MG-63 cell cytoplasm.
- Anti-TPD52 antiserum demonstrated dose-dependent inhibition of osteosarcoma cell proliferation and in vivo tumor growth (61.95% inhibition at 100 μg).
- Treatment increased serum IFN-γ, TNF-α, and IL-12 levels, induced apoptosis, and showed no significant histopathological damage.
Conclusions:
- Anti-TPD52 antiserum effectively inhibits osteosarcoma.
- The mechanism involves inducing apoptosis in cancer cells.
- This therapeutic strategy appears safe, with no observed histopathological damage.
